+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Parkinson's Disease - Pipeline Review, H2 2020

  • ID: 5189073
  • Drug Pipelines
  • October 2020
  • Region: Global
  • 1308 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • Alector Inc
  • Aptamer Sciences Inc
  • AZTherapies Inc
  • Calico LLC
  • CereSpir Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H2 2020, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 48, 62, 4, 224, 97 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 52 and 19 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • Alector Inc
  • Aptamer Sciences Inc
  • AZTherapies Inc
  • Calico LLC
  • CereSpir Inc
  • MORE
  • Introduction
  • Parkinson's Disease - Overview
  • Parkinson's Disease - Therapeutics Development
  • Parkinson's Disease - Therapeutics Assessment
  • Parkinson's Disease - Companies Involved in Therapeutics Development
  • Parkinson's Disease - Drug Profiles
  • Parkinson's Disease - Dormant Projects
  • Parkinson's Disease - Discontinued Products
  • Parkinson's Disease - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Parkinson's Disease, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Parkinson's Disease - Pipeline by 1st Bio Therapeutics Inc, H2 2020
  • Parkinson's Disease - Pipeline by 4D Pharma Plc, H2 2020
  • Parkinson's Disease - Pipeline by Abaxy Sprl, H2 2020
  • Parkinson's Disease - Pipeline by AbbVie Inc, H2 2020
  • Parkinson's Disease - Pipeline by Abfero Pharmaceuticals Inc, H2 2020
  • Parkinson's Disease - Pipeline by Abivax SA, H2 2020
  • Parkinson's Disease - Pipeline by ABL Bio Inc, H2 2020
  • Parkinson's Disease - Pipeline by AC Immune SA, H2 2020
  • Parkinson's Disease - Pipeline by Accure Therapeutics SL, H2 2020
  • Parkinson's Disease - Pipeline by Acelot Inc, H2 2020
  • Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2020
  • Parkinson's Disease - Pipeline by Adicet Bio Inc, H2 2020
  • Parkinson's Disease - Pipeline by Affichem SA, H2 2020
  • Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2020
  • Parkinson's Disease - Pipeline by Carmot Therapeutics Inc, H2 2020
  • Parkinson's Disease - Pipeline by Carna Biosciences Inc, H2 2020
  • Parkinson's Disease - Pipeline by Casma Therapeutics Inc, H2 2020
  • Parkinson's Disease - Pipeline by Cavion LLC, H2 2020
  • Parkinson's Disease - Pipeline by CavoGene LifeSciences, H2 2020
  • Parkinson's Disease - Pipeline by Celavie Biosciences LLC, H2 2020
  • Parkinson's Disease - Pipeline by CellCure, H2 2020
  • Parkinson's Disease - Pipeline by Cellivery Therapeutics Inc, H2 2020
  • Parkinson's Disease - Pipeline by Cellix Bio Pvt Ltd, H2 2020
  • Parkinson's Disease - Pipeline by Cerecin Inc, H2 2020
  • Parkinson's Disease - Pipeline by Cerecor Inc, H2 2020
  • Parkinson's Disease - Pipeline by CereSpir Inc, H2 2020
  • Parkinson's Disease - Pipeline by Cerevance Inc, H2 2020
  • Parkinson's Disease - Pipeline by Cerevel Therapeutics LLC, H2 2020
  • Parkinson's Disease - Pipeline by CHA Biotech Co Ltd, H2 2020
  • Parkinson's Disease - Pipeline by Chamishi Therapeutics Inc, H2 2020
  • Parkinson's Disease - Pipeline by Chase Therapeutics Corp, H2 2020
  • Parkinson's Disease - Pipeline by Chiesi Farmaceutici SpA, H2 2020
  • Parkinson's Disease - Pipeline by CholesteniX Ltd, H2 2020
  • Parkinson's Disease - Pipeline by Chongqing Pharmaceutical Research Institute Co Ltd, H2 2020
  • Parkinson's Disease - Pipeline by Ci Therapeutics, H2 2020
  • Parkinson's Disease - Pipeline by Clayton Biotechnologies Inc, H2 2020
  • Parkinson's Disease - Pipeline by Clene Nanomedicine Inc, H2 2020
  • Parkinson's Disease - Pipeline by Clevexel Pharma SA, H2 2020
  • Parkinson's Disease - Pipeline by InnoMedica Holding AG, H2 2020
  • Parkinson's Disease - Pipeline by Intec Pharma Ltd, H2 2020
  • Parkinson's Disease - Pipeline by International Stem Cell Corp, H2 2020
  • Parkinson's Disease - Pipeline by Intra-Cellular Therapies Inc, H2 2020
  • Parkinson's Disease - Pipeline by Invisio Ltd, H2 2020
  • Parkinson's Disease - Pipeline by Io Therapeutics Inc, H2 2020
  • Parkinson's Disease - Pipeline by Ionis Pharmaceuticals Inc, H2 2020
  • Parkinson's Disease - Pipeline by IRLAB Therapeutics AB, H2 2020
  • Parkinson's Disease - Pipeline by Jazz Pharmaceuticals Plc, H2 2020
  • Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2020
  • Parkinson's Disease - Pipeline by Junaxo Inc, H2 2020
  • Parkinson's Disease - Pipeline by Kainos Medicine Inc, H2 2020
  • Parkinson's Disease - Pipeline by Kariya Pharmaceuticals IVS, H2 2020
  • Parkinson's Disease - Dormant Projects, H2 2020
  • Parkinson's Disease - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Parkinson's Disease, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • 1st Bio Therapeutics Inc
  • 4D Pharma Plc
  • Abaxy Sprl
  • AbbVie Inc
  • Abfero Pharmaceuticals Inc
  • Abivax SA
  • ABL Bio Inc
  • AC Immune SA
  • Accure Therapeutics SL
  • Acelot Inc
  • Addex Therapeutics Ltd
  • Adicet Bio Inc
  • Affichem SA
  • AFFiRiS AG
  • AgoneX Biopharmaceuticals Inc
  • Alan Laboratories Inc
  • Alector Inc
  • Alectos Therapeutics
  • Alexza Pharmaceuticals Inc
  • Alkahest Inc
  • Alkermes Plc
  • Allife Medical Science and Technology Co Ltd
  • AlphaCognition Inc
  • Alsonex Pty Ltd
  • Alterity Therapeutics Ltd
  • Amathus Therapeutics Inc
  • Amneal Pharmaceuticals Inc
  • Anavex Life Sciences Corp
  • Annovis Bio Inc
  • Antoxis Ltd
  • Aoxing Pharmaceutical Company Inc
  • Apollo Therapeutics LLC
  • Appello Pharmaceuticals Inc
  • Aprinoia Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Aptamer Sciences Inc
  • Araclon Biotech SL
  • Aranda Pharma Ltd
  • AriBio
  • ArmaGen Inc
  • Arrien Pharmaceuticals LLC
  • Arvinas Inc
  • Asdera LLC
  • Asklepios BioPharmaceutical Inc
  • Aspen Neuroscience Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Athersys Inc
  • Athira Pharma Inc
  • Auritec Pharmaceuticals Inc
  • Avicanna Inc
  • Axial Biotherapeutics Inc
  • Axovant Gene Therapies Ltd
  • AZTherapies Inc
  • Azymus Therapeutics Inc
  • B&A Therapeutics
  • BCWorld Pharm Co Ltd
  • Belrose Pharma Inc
  • Berg LLC
  • Better Life Pharmaceuticals Inc
  • Bial - Portela & Ca SA
  • Bio-Modeling Systems SAS
  • Bio-Pharm Solutions Co Ltd
  • Bioasis Technologies Inc
  • Biogen Inc
  • Biorchestra Ltd
  • BlueRock Therapeutics
  • Bopin (Shanghai) Biomedical Technology Co Ltd
  • BrainEver SAS
  • BrainStorm Cell Therapeutics Inc
  • Bristol-Myers Squibb Co
  • C4X Discovery Holdings Plc
  • Calico LLC
  • Califia Bio Inc
  • Cantabio Pharmaceuticals Inc
  • Canvax Biotech SL
  • Capo Therapeutics Inc
  • Carmot Therapeutics Inc
  • Carna Biosciences Inc
  • Casma Therapeutics Inc
  • Cavion LLC
  • CavoGene LifeSciences
  • Celavie Biosciences LLC
  • CellCure
  • Cellivery Therapeutics Inc
  • Cellix Bio Pvt Ltd
  • Cerecin Inc
  • Cerecor Inc
  • CereSpir Inc
  • Cerevance Inc
  • Cerevel Therapeutics LLC
  • CHA Biotech Co Ltd
  • Chamishi Therapeutics Inc
  • Chase Therapeutics Corp
  • Chiesi Farmaceutici SpA
  • CholesteniX Ltd
  • Chongqing Pharmaceutical Research Institute Co Ltd
  • Ci Therapeutics
  • Clayton Biotechnologies Inc
  • Clene Nanomedicine Inc
  • Clevexel Pharma SA
  • Clexio Biosciences Ltd
  • Cogentis Therapeutics Inc
  • Collaborative Medicinal Development LLC
  • Contera Pharma ApS
  • Copernicus Therapeutics Inc
  • Corium Inc
Note: Product cover images may vary from those shown
Adroll
adroll